Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    Mepsevii for MPS VII Reimbursement Approval Available in Spain
    source: pixabay.com

    Mepsevii for MPS VII Reimbursement Approval Available in Spain

    According to a recent news release from biopharmaceutical company Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), the company's therapy Mepsevii (vestronidase alfa) was approved in Spain for reimbursement. The entire reimbursement process takes…

    Continue Reading Mepsevii for MPS VII Reimbursement Approval Available in Spain
    New Data Available on KEVEYIS for PPP
    https://unsplash.com/photos/8ztH-7lj8ag

    New Data Available on KEVEYIS for PPP

    In a news release from mid-July, 2021, biopharmaceutical company Strongbridge Biopharma plc ("Strongbridge") shared the publication of new post hoc analyses regarding KEVEYIS (dichlorphenamide) for patients with Primary Periodic Paralysis…

    Continue Reading New Data Available on KEVEYIS for PPP
    First Patient Dosed in IVIG Study for PI
    Source: https://pixabay.com/en/hospital-infusion-drip-antibiotic-834152/

    First Patient Dosed in IVIG Study for PI

      According to a July 13 news release, biopharmaceutical company Kedrion Biopharma ("Kedrion") recently treated its first pediatric patient within the Phase 3 KIDCARES10 clinical trial. Within the trial, Kedrion…

    Continue Reading First Patient Dosed in IVIG Study for PI
    FRC Test Detects CF in Newborn Screening
    source: pixabay.com

    FRC Test Detects CF in Newborn Screening

    Have you ever heard of newborn screening? Basically, newborn screening is a public health service which can identify potential hormone-related, genetic, or metabolic conditions. Since early identification is so crucial…

    Continue Reading FRC Test Detects CF in Newborn Screening